Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment
2018; Future Medicine; Volume: 19; Issue: 18 Linguagem: Inglês
10.2217/pgs-2018-0113
ISSN1744-8042
AutoresÁngela Gutiérrez-Camino, Maitane Umerez, Elixabet López-López, Borja Santos-Zorrozúa, Idoia Martín‐Guerrero, Nagore García de Andoín, Sastre Ana, Aurora Navajas, Itziar Astigarraga, África García‐Orad,
Tópico(s)Neonatal Health and Biochemistry
ResumoAim: Mucositis, linked to methotrexate, daunorubicin or cyclophosphamide, is a frequent childhood acute lymphoblastic leukemia (ALL) therapy side effect. miRNAs regulate the expression of pharmacokinetic/pharmacodynamic pathway genes. SNPs in miRNAs could affect their levels or function, and affect their pharmacokinetic/pharmacodynamic pathway target genes. Our aim was to determine the association between miRNA genetic variants targeting mucositis-related genes and mucositis-developing risk. Patients & methods: We analyzed 160 SNPs in 179 Spanish children with B-cell precursor ALL homogeneously treated with LAL/SHOP protocols. Results: We identified three SNPs in miR-4268, miR-4751 and miR-3117 associated with mucositis, diarrhea and vomiting, respectively. Conclusion: The effect of these SNPs on genes related to drug pharmacokinetics/pharmacodynamics could explain mucositis, diarrhea and vomiting development during ALL therapy.
Referência(s)